Mannkind Corporation's Afrezza is positioned in the competitive landscape of diabetes management, particularly for patients with Type 1 and Type 2 diabetes. The Dosing Optimization Study (MKC-TI-191) aims to enhance the understanding of Afrezza's efficacy in conjunction with basal insulin, potentially improving patient adherence and glycemic control. The results could strengthen Afrezza's market positioning against traditional insulin therapies and other inhaled insulin products. The study's completion and subsequent data may attract interest from healthcare providers and payers, influencing market uptake and reimbursement strategies.